Association between diabetes and prevalence and growth rate of abdominal aortic aneurysms: A meta-analysis

International Journal of Cardiology

Volumn 221, Issue , 2016, Pages 484-495

  Xiong, Jiang ^a   Wu, Zhongyin ^a   Chen, Chen ^b   Wei, Yingqi ^c   Guo, Wei ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b GEORGIA SOUTHERN UNIVERSITY   (United States)

^c CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

Abdominal aortic aneurysm; Diabetes; Growth rate; Meta analysis; Prevalence

Indexed keywords

ABDOMINAL AORTA ANEURYSM; ARTICLE; ASIA; AUSTRALIA; CASE CONTROL STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; EUROPEAN; GEOGRAPHY; HUMAN; NORTH AMERICAN; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCREENING; SOUTH AMERICA; AORTIC ANEURYSM, ABDOMINAL; META ANALYSIS; RISK FACTOR;

AORTIC ANEURYSM, ABDOMINAL; CASE-CONTROL STUDIES; DIABETES MELLITUS; HUMANS; PREVALENCE; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84978036845     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.07.016     Document Type: Article

References (54)

1. [1] Svensjo, S., Bjorck, M., Gurtelschmid, M., Djavani Gidlund, K., Hellberg, A., Wanhainen, A., Low prevalence of abdominal aortic aneurysm among 65-year-old Swedish men indicates a change in the epidemiology of the disease. Circulation 124 (2011), 1118–1123.
2. [2] Kent, K.C., Zwolak, R.M., Egorova, N.N., et al. Analysis of risk factors for abdominal aortic aneurysm in a cohort of more than 3 million individuals. J. Vasc. Surg. 52 (2010), 539–548.
3. [3] Torsney, E., Pirianov, G., Cockerill, G.W., Diabetes as a negative risk factor for abdominal aortic aneurysm — does the disease aetiology or the treatment provide the mechanism of protection?. Curr. Vasc. Pharmacol. 11 (2013), 293–298.
4. [4] Beckman, J.A., Creager, M.A., Libby, P., Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 287 (2002), 2570–2581.
5. [5] Skyler, J.S., Bergenstal, R., Bonow, R.O., et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 32 (2009), 187–192.
6. [6] Gerstein, H.C., Miller, M.E., Byington, R.P., et al. Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med. 358 (2008), 2545–2559.
7. [7] Patel, A., MacMahon, S., Chalmers, J., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 358 (2008), 2560–2572.
8. [8] Duckworth, W., Abraira, C., Moritz, T., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N. Engl. J. Med. 360 (2009), 129–139.
9. [9] Shantikumar, S., Ajjan, R., Porter, K.E., Scott, D.J., Diabetes and the abdominal aortic aneurysm. Eur. J. Vasc. Endovasc. Surg. 39 (2010), 200–207.
10. [10] De Rango, P., Farchioni, L., Fiorucci, B., Lenti, M., Diabetes and abdominal aortic aneurysms. Eur. J. Vasc. Endovasc. Surg. 47 (2014), 243–261.
11. [11] Chang, J.B., Stein, T.A., Liu, J.P., Dunn, M.E., Risk factors associated with rapid growth of small abdominal aortic aneurysms. Surgery 121 (1997), 117–122.
12. [12] Stang, A., Critical evaluation of the Newcastle–Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur. J. Epidemiol. 25 (2010), 603–605.
13. [13] Escrig-Sos, J., On how to analyze the credibility of a clinical trial or meta-analysis whose main result is expressed in odds ratio, relative risk or hazard ratio. Cir. Esp. 78 (2005), 351–356.
14. [14] Raboisson, D., Mounie, M., Maigne, E., Diseases, reproductive performance, and changes in milk production associated with subclinical ketosis in dairy cows: a meta-analysis and review. J. Dairy Sci. 97 (2014), 7547–7563.
15. [15] Wang, S., Zhang, Z., Liu, M., Li, S., Jiang, C., Endoscopic resection compared with gastrectomy to treat early gastric cancer: a systematic review and meta-analysis. PLoS One, 10, 2015, e0144774.
16. [16] Ungprasert, P., Thongprayoon, C., Warrington, K.J., Lower body mass index is associated with a higher risk of giant cell arteritis: a systematic review and meta-analysis. Ann. Transl. Med., 3, 2015, 232.
17. [17] Lederle, F.A., Walker, J.M., Reinke, D.B., Selective screening for abdominal aortic aneurysms with physical examination and ultrasound. Arch. Intern. Med. 148 (1988), 1753–1756.
18. [18] Smith, F.C., Grimshaw, G.M., Paterson, I.S., Shearman, C.P., Hamer, J.D., Ultrasonographic screening for abdominal aortic aneurysm in an urban community. Br. J. Surg. 80 (1993), 1406–1409.
19. [19] Simoni, G., Pastorino, C., Perrone, R., et al. Screening for abdominal aortic aneurysms and associated risk factors in a general population. Eur. J. Vasc. Endovasc. Surg. 10 (1995), 207–210.
20. [20] Pleumeekers, H.J., Hoes, A.W., van der Does, E., et al. Aneurysms of the abdominal aorta in older adults. The Rotterdam Study. Am. J. Epidemiol. 142 (1995), 1291–1299.
21. [21] LaMorte, W.W., Scott, T.E., Menzoian, J.O., Racial differences in the incidence of femoral bypass and abdominal aortic aneurysmectomy in Massachusetts: relationship to cardiovascular risk factors. J. Vasc. Surg. 21 (1995), 422–431.
22. [22] Kanagasabay, R., Gajraj, H., Pointon, L., Scott, R.A., Co-morbidity in patients with abdominal aortic aneurysm. J. Med. Screen. 3 (1996), 208–210.
23. [23] Alcorn, H.G., Wolfson, S.K. Jr., Sutton-Tyrrell, K., Kuller, L.H., O'Leary, D., Risk factors for abdominal aortic aneurysms in older adults enrolled in The Cardiovascular Health Study. Arterioscler. Thromb. Vasc. Biol. 16 (1996), 963–970.
24. [24] Lederle, F.A., Johnson, G.R., Wilson, S.E., et al. Prevalence and associations of abdominal aortic aneurysm detected through screening. Aneurysm Detection and Management (ADAM) Veterans Affairs Cooperative Study Group. Ann. Intern. Med. 126 (1997), 441–449.
25. [25] Mattes, E., Davis, T.M., Yang, D., Ridley, D., Lund, H., Norman, P.E., Prevalence of abdominal aortic aneurysms in men with diabetes. Med. J. Aust. 166 (1997), 630–633.
26. [26] Mann, C.J., Observational research methods. Research design II: cohort, cross sectional, and case–control studies. Emerg. Med. J. 20 (2003), 54–60.
27. [27] Hiatt, W.R., Medical treatment of peripheral arterial disease and claudication. N. Engl. J. Med. 344 (2001), 1608–1621.
28. [28] Prakash, S.K., Pedroza, C., Khalil, Y.A., Milewicz, D.M., Diabetes and reduced risk for thoracic aortic aneurysms and dissections: a nationwide case–control study. J. Am. Heart Assoc., 1, 2012.
29. [29] Shteinberg, D., Halak, M., Shapiro, S., et al. Abdominal aortic aneurysm and aortic occlusive disease: a comparison of risk factors and inflammatory response. Eur. J. Vasc. Endovasc. Surg. 20 (2000), 462–465.
30. [30] Barba, A., Estallo, L., Rodriguez, L., Baquer, M., Vega de Ceniga, M., Detection of abdominal aortic aneurysm in patients with peripheral artery disease. Eur. J. Vasc. Endovasc. Surg. 30 (2005), 504–508.
31. [31] Koksal, C., Ercan, M., Bozkurt, A.K., Cortelekoglu, T., Konukoglu, D., Abdominal aortic aneurysm or aortic occlusive disease: role of trace element imbalance. Angiology 58 (2007), 191–195.
32. [32] Ito, S., Akutsu, K., Tamori, Y., et al. Differences in atherosclerotic profiles between patients with thoracic and abdominal aortic aneurysms. Am. J. Cardiol. 101 (2008), 696–699.
33. [33] Sweeting, M.J., Thompson, S.G., Brown, L.C., Powell, J.T., Meta-analysis of individual patient data to examine factors affecting growth and rupture of small abdominal aortic aneurysms. Br. J. Surg. 99 (2012), 655–665.
34. [34] Santilli, S.M., Littooy, F.N., Cambria, R.A., et al. Expansion rates and outcomes for the 3.0-cm to the 3.9-cm infrarenal abdominal aortic aneurysm. J. Vasc. Surg. 35 (2002), 666–671.
35. [35] Golledge, J., Karan, M., Moran, C.S., et al. Reduced expansion rate of abdominal aortic aneurysms in patients with diabetes may be related to aberrant monocyte-matrix interactions. Eur. Heart J. 29 (2008), 665–672.
36. [36] Ferguson, C.D., Clancy, P., Bourke, B., et al. Association of statin prescription with small abdominal aortic aneurysm progression. Am. Heart J. 159 (2010), 307–313.
37. [37] De Rango, P., Cao, P., Cieri, E., et al. Effects of diabetes on small aortic aneurysms under surveillance according to a subgroup analysis from a randomized trial. J. Vasc. Surg. 56 (2012), 1555–1563.
38. [38] Vavuranakis, M., Stefanadis, C., Toutouzas, K., Pitsavos, C., Spanos, V., Toutouzas, P., Impaired compensatory coronary artery enlargement in atherosclerosis contributes to the development of coronary artery stenosis in diabetic patients. An in vivo intravascular ultrasound study. Eur. Heart J. 18 (1997), 1090–1094.
39. [39] Androulakis, A.E., Andrikopoulos, G.K., Kartalis, A.N., et al. Relation of coronary artery ectasia to diabetes mellitus. Am. J. Cardiol. 93 (2004), 1165–1167.
40. [40] Huang, Q.J., Liu, J., Chen, M.H., Li, J.J., Relation of diabetes to coronary artery ectasia: a meta-analysis study. Anadolu Kardiyol. Derg. (Trans.) Anatol. J. Cardiol., 2014.
41. [41] Bronner, L.L., Kanter, D.S., Manson, J.E., Primary prevention of stroke. N. Engl. J. Med. 333 (1995), 1392–1400.
42. [42] Go, A.S., Mozaffarian, D., Roger, V.L., et al. Executive summary: heart disease and stroke statistics—2014 update: a report from the American Heart Association. Circulation 129 (2014), 399–410.
43. [43] Dailey, G., Early and intensive therapy for management of hyperglycemia and cardiovascular risk factors in patients with type 2 diabetes. Clin. Ther. 33 (2011), 665–678.
44. [44] Reaven, P.D., Moritz, T.E., Schwenke, D.C., et al. Intensive glucose-lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis. Diabetes 58 (2009), 2642–2648.
45. [45] Bergqvist, D., Pharmacological interventions to attenuate the expansion of abdominal aortic aneurysm (AAA) — a systematic review. Eur. J. Vasc. Endovasc. Surg. 41 (2011), 663–667.
46. [46] Thompson, A., Cooper, J.A., Fabricius, M., Humphries, S.E., Ashton, H.A., Hafez, H., An analysis of drug modulation of abdominal aortic aneurysm growth through 25 years of surveillance. J. Vasc. Surg. 52 (2010), 55–61 e2.
47. [47] Kaschina, E., Schrader, F., Sommerfeld, M., et al. Telmisartan prevents aneurysm progression in the rat by inhibiting proteolysis, apoptosis and inflammation. J. Hypertens. 26 (2008), 2361–2373.
48. [48] Moran, C.S., Clancy, P., Biros, E., et al. Association of PPARgamma allelic variation, osteoprotegerin and abdominal aortic aneurysm. Clin. Endocrinol. 72 (2010), 128–132.
49. [49] Jones, A., Deb, R., Torsney, E., et al. Rosiglitazone reduces the development and rupture of experimental aortic aneurysms. Circulation 119 (2009), 3125–3132.
50. [50] Golledge, J., Cullen, B., Rush, C., et al. Peroxisome proliferator-activated receptor ligands reduce aortic dilatation in a mouse model of aortic aneurysm. Atherosclerosis 210 (2010), 51–56.
51. [51] Miyama, N., Dua, M.M., Yeung, J.J., et al. Hyperglycemia limits experimental aortic aneurysm progression. J. Vasc. Surg. 52 (2010), 975–983.
52. [52] Iida, Y., Xu, B., Xuan, H., et al. Peptide inhibitor of CXCL4-CCL5 heterodimer formation, MKEY, inhibits experimental aortic aneurysm initiation and progression. Arterioscler. Thromb. Vasc. Biol. 33 (2013), 718–726.
53. [53] Bao, W., Morimoto, K., Hasegawa, T., et al. Orally administered dipeptidyl peptidase-4 inhibitor (alogliptin) prevents abdominal aortic aneurysm formation through an antioxidant effect in rats. J. Vasc. Surg. 59 (2014), 1098–1108.
54. [54] Svensjo, S., Bjorck, M., Wanhainen, A., Current prevalence of abdominal aortic aneurysm in 70-year-old women. Br. J. Surg. 100 (2013), 367–372.